LIONHEART VENTURES — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Cognigenicscognigenics.ioinJun 2022
Cognigenics is developing iRNAi, a non-invasive intranasal RNA interference platform that delivers programmable RNA therapeutics directly to targeted brain circuits, bypassing the blood-brain barrier to modulate mood, memory, and cognition.
BiotechDeep TechDigital HealthEagle, US
John Mee(Mr. Mee is a promoter, director and officer of the company.)Barry Linder(Executive Officer, Director, Promoter)Dean Radin(Executive Officer, Director, Promoter)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.